Consultation
We ask for feedback on proposals through public consultation, and take all consultation responses we receive into account before making our decisions. PHARMAC has published guidance for consumers on getting involved in our decisions, and this includes responses to consultation. You can download the document here (8 pages, 100 KB).
We welcome feedback from pharmaceutical suppliers, health professionals, health interest groups and the general public. This page includes consultations that are currently underway.
You can respond to consultation by writing to the address at the bottom of the consultation letter.
Rapid response
If you would like to make a rapid response to any of our consultations, 
click here. Remember to indicate which consultation proposal your comments relate to.
Search for previous consultations documents
- Proposal for funding potassium iodate. Closes 17 July. (2 pages, 132 KB) 03 Jul 2009
- Proposal to fund healthE Fatty Cream (oil in water emulsion). Closes 10 July (1 page, 54 KB) 26 Jun 2009
- Proposal for sole supply arrangement for sumatriptan. Closes 4pm, 8 July (3 pages, 137 KB) 23 Jun 2009
- Proposal to Reference Price Betaloc CR to AFT-Metoprolol CR. Closes 10 July (4 pages, 177 KB) 22 Jun 2009
- Proposal to remove restriction from DP-Anastrozole - Closes 1 July (2 pages, 199 KB) 18 Jun 2009
- Funding proposal for Lantus, Apidra and Betadine. Closed (3 pages, 232 KB) 15 Jun 2009
- Proposal relating to cyclosporin A and clozapine. Closed. (1 page, 168 KB) 15 Jun 2009
- Proposal to list Hypertonic Saline (7% sodium chloride solution) in the Pharmaceutical Schedule for use in Cystic Fibrosis. Closed. (2 pages, 108 KB) 10 Jun 2009
- Proposal to list a new brand of tamoxifen. Closed. (1 page, 39 KB) 05 Jun 2009
- Proposal to list Clarithromycin 500 mg tablets. Closed. (2 pages, 57 KB) 29 May 2009
- Proposal to list low molecular weight heparin. Closed. (4 pages, 61 KB) 29 May 2009
- Proposal to list pegfilgrastim (Neulastim) on the Discretionary Community Supply list. Closed. (2 pages, 159 KB) 28 May 2009
- Proposal for Mylan risperidone, lithium, quetiapine. Closed. (2 pages, 50 KB) 27 May 2009
- Provisional agreement with Baxter Healthcare for volatile anaesthetics. Closed. (2 pages, 56 KB) 18 May 2009
- Consultation letter for version 2 of the Funding Application Guidelines. Closes 1 July (2 pages, 43 KB) 14 May 2009
- Draft version 2 of the Funding Application Guidelines. Closes 1 July 2009 (46 pages, 396 KB) 13 May 2009
- Proposal to fund mirtazapine. Closed. (2 pages, 121 KB) 06 May 2009
- Proposal relating to adalimumab, leuprorelin and levothyroxine and other autoimmune biologic community funding applications. Closed. (8 pages, 80 KB) 05 May 2009
- Input into the Consumer Advisory Committee Terms of Reference Review. Closed. (25 pages, 392 KB) 04 May 2009
- Proposal relating to valaciclovir, bupropion and various respiratory products. Closed. (3 pages, 59 KB) 04 May 2009
Page updated on 03 Jul 2009
Linked documents
Having Your Say in our Decisions (8 pages, 100 KB)
Pharmaceutical Management Agency Having your say in our decisions PHARMAC’s decision-making PHARMAC is the Government agency that decides which medicines are funded for New Zealanders. We welcome input from people into our decision-making processes. There are a number of ways…
Proposal for funding potassium iodate. Closes 17 July. (2 pages, 132 KB)
3 July 2009 Proposal for funding potassium iodate Proposal summary PHARMAC is seeking feedback on a proposal to fund an iodine supplement for the treatment of iodine deficiency with effect from 1 September 2009. Further details of the proposal can…
Proposal to fund healthE Fatty Cream (oil in water emulsion). Closes 10 July (1 page, 54 KB)
26 June 2009 Proposal to fund healthE Fatty Cream (oil in water emulsion) PHARMAC is seeking feedback on a proposal to fund a new brand of oil in water emulsion cream (healthE Fatty Cream) on the Pharmaceutical Schedule. This proposal…
Proposal for sole supply arrangement for sumatriptan. Closes 4pm, 8 July (3 pages, 137 KB)
23 June 2009 Proposal for sole supply arrangement for sumatriptan Proposal summary PHARMAC and Arrow Pharmaceuticals (NZ) Ltd have reached a provisional agreement for the supply of Arrow-Sumatriptan, one of the three brands of sumatriptan tablets currently funded by PHARMAC.…
Proposal to Reference Price Betaloc CR to AFT-Metoprolol CR. Closes 10 July (4 pages, 177 KB)
19 June 2009 Proposal to Reference Price Betaloc CR to AFT-Metoprolol CR Summary • Metoprolol succinate is a medicine used to treat high blood pressure, and heart failure. It is currently supplied by AstraZeneca Ltd under the brand name Betaloc…
Proposal to remove restriction from DP-Anastrozole - Closes 1 July (2 pages, 199 KB)
17 June 2009 Proposal to remove the restriction from DP-Anastrozole Proposal PHARMAC proposes to remove the restriction (endorsement criteria) which applies to the prescribing and dispensing of Douglas Pharmaceuticals Ltd’s brand of the aromatase inhibitor anastrozole (DP-Anastrozole). The current subsidy…
Funding proposal for Lantus, Apidra and Betadine. Closed (3 pages, 232 KB)
15 June 2009 Funding proposal for Lantus (insulin glargine), Apidra (insulin glulisine) and Betadine (povidone iodine) Proposal summary PHARMAC and Sanofi-Aventis New Zealand Ltd have entered into a provisional agreement that would result in widening access to a long-acting insulin…
Proposal relating to cyclosporin A and clozapine. Closed. (1 page, 168 KB)
15 June 2009 Proposal relating to cyclosporin A and clozapine PHARMAC and Novartis New Zealand Limited have entered into a provisional agreement relating to the supply of Neoral (cyclosporin A 25 mg, 50 mg and 100 mg capsules and 100…
Proposal to list Hypertonic Saline (7% sodium chloride solution) in the Pharmaceutical Schedule for use in Cystic Fibrosis. Closed. (2 pages, 108 KB)
10 June 2009 Proposal to list Hypertonic Saline (7% sodium chloride solution) in the Pharmaceutical Schedule for use in Cystic Fibrosis Proposal Summary PHARMAC is seeking feedback on a proposal to list hypertonic saline (7% sodium chloride solution) in Sections…
Proposal to list a new brand of tamoxifen. Closed. (1 page, 39 KB)
5 June 2009 Proposal to list a new brand of tamoxifen (Tamoxifen Sandoz) PHARMAC is seeking feedback on a proposal to list an additional brand of tamoxifen citrate (Tamoxifen Sandoz) in the Pharmaceutical Schedule. Details of the proposal PHARMAC and…
Proposal to list Clarithromycin 500 mg tablets. Closed. (2 pages, 57 KB)
29 May 2009 Proposal to list Clarithromycin 500 mg tablets PHARMAC is seeking feedback on a proposal to fund clarithromycin 500 mg tablets (Klamycin) on the Pharmaceutical Schedule. In summary, this proposal would result in: • • • Klamycin 500…
Proposal to list low molecular weight heparin. Closed. (4 pages, 61 KB)
29 May 2009 Proposal to list low molecular weight heparin in the Pharmaceutical Schedule Proposal Summary PHARMAC is seeking feedback on a proposal to list one brand of low molecular weight heparin in Section B of the Pharmaceutical Schedule from…
Proposal to list pegfilgrastim (Neulastim) on the Discretionary Community Supply list. Closed. (2 pages, 159 KB)
28 May 2009 Proposal to list pegfilgrastim (Neulastim) on the Discretionary Community Supply list PHARMAC is seeking feedback on a proposal to list pegfilgrastim on Part IV of Section H of the Pharmaceutical Schedule (Discretionary Community Supply). In summary, this…
Proposal for Mylan risperidone, lithium, quetiapine. Closed. (2 pages, 50 KB)
27 May 2009 Proposal for Mylan risperidone, lithium carbonate and quetiapine PHARMAC is seeking feedback on a proposal to fund a new brand of risperidone oral liquid (Risperon), and to amend the terms of listing of the Lithicarb brand of…
Provisional agreement with Baxter Healthcare for volatile anaesthetics. Closed. (2 pages, 56 KB)
18 May 2009 Proposal to list and apply Hospital Supply Status to Baxter Healthcare’s brands of desflurane, sevoflurane and isoflurane PHARMAC is seeking feedback on a proposal to list Baxter Healthcare’s brands of desflurane (Suprane), sevoflurane (Baxter-sevoflurane), and isoflurane (Aerrane)…
Consultation letter for version 2 of the Funding Application Guidelines. Closes 1 July (2 pages, 43 KB)
14 May 2009 To all Pharmaceutical Suppliers and Interested Parties Consultation on Revised Funding Application Guidelines We are now inviting submissions on the revised Funding Application Guidelines. We hope you will take the time to make a submission, and we…
Draft version 2 of the Funding Application Guidelines. Closes 1 July 2009 (46 pages, 396 KB)
Guidelines for Funding Applications to PHARMAC Version 2 2009 Foreword PHARMAC, the Pharmaceutical Management Agency, is primarily responsible for managing the funding of community pharmaceuticals for New Zealanders, on behalf of the District Health Boards. PHARMAC’s objective is to secure…
Proposal to fund mirtazapine. Closed. (2 pages, 121 KB)
6 May 2009 Proposal to fund mirtazapine for depression Proposal summary PHARMAC is seeking feedback on a proposal to fund the antidepressant mirtazapine (Avanza) as soon as possible following receipt of the necessary Medsafe consents, through a provisional agreement with…
Proposal relating to adalimumab, leuprorelin and levothyroxine and other autoimmune biologic community funding applications. Closed. (8 pages, 80 KB)
5 May 2009 Proposal relating to adalimumab, leuprorelin and levothyroxine and other autoimmune biologic community funding applications Proposal summary PHARMAC is seeking feedback on a proposal to widen funded access to adalimumab for treatment of ankylosing spondylitis, Crohn’s disease, severe…
Input into the Consumer Advisory Committee Terms of Reference Review. Closed. (25 pages, 392 KB)
1 May 2009 INPUT INTO THE CONSUMER ADVISORY COMMITTEE TERMS OF REFERENCE REVIEW We’d like to benefit from your views on how PHARMAC can best utilise its Consumer Advisory Committee (CAC). At present we are not making any proposals; we…
Proposal relating to valaciclovir, bupropion and various respiratory products. Closed. (3 pages, 59 KB)
4 May 2009 Proposal relating to valaciclovir, bupropion and various respiratory products PHARMAC is seeking feedback on a proposal relating to a provisional agreement signed with GlaxoSmithKline for a number of products. In summary, the proposal would result in: the…
